Form 4: Orthofix Director John Henneman III Receives Significant Deferred Stock Unit Award

Orthofix Medical Inc. Director John B. Henneman III was granted 18,841 deferred stock units, increasing his beneficial ownership to 83,706 shares.

Summary

• John B. Henneman III, a Director of Orthofix Medical Inc. (OFIX), received an award of 18,841 deferred stock units (DSUs) on June 18, 2025.
• These DSUs represent a contingent right to receive one share of Orthofix common stock per unit.
• The awarded DSUs are scheduled to vest in full on the first anniversary of the grant date, contingent upon Mr. Henneman's continued service to the company.
• Upon vesting, these deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.
• Following this transaction, Mr. Henneman's total beneficial ownership in Orthofix Medical Inc. stands at 83,706 shares.
• This total beneficial ownership includes 29,506 previously reported deferred stock units and 951 shares acquired under Orthofix's Stock Purchase Plan on April 30, 2025.

Sentiment

Score: 7

Explanation: The filing indicates a director receiving an equity award, which is generally viewed positively as it aligns the director's financial interests with the long-term performance of the company and its shareholders.

Positives

• Director John B. Henneman III received an award of 18,841 deferred stock units, which aligns his financial interests with the long-term performance and shareholder value of Orthofix Medical Inc.
• The vesting schedule of the award, which occurs on the first anniversary of the grant date subject to continued service, incentivizes the director's ongoing commitment and contribution to the company.

Future Outlook

The 18,841 deferred stock units granted to Director John B. Henneman III are scheduled to vest in full on the first anniversary of the grant date (June 18, 2026), contingent upon his continued service to the company. Vested units will convert to common stock within 45 days of his termination of service.

Industry Context

This Form 4 details a routine equity compensation award to a director, which is a common practice across industries to align management and director incentives with shareholder interests and promote long-term value creation.

Corporate Governance

Related Party Transactions

• Award of 18,841 deferred stock units to Director John B. Henneman III as part of his compensation package.
• Acquisition of 951 shares by Director John B. Henneman III under Orthofix's Stock Purchase Plan.

Stakeholder Impact

• Shareholders: The equity award to a director aligns management's interests with shareholder value creation, potentially fostering long-term growth.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The 18,841 deferred stock units are expected to vest on the first anniversary of the grant date (June 18, 2026), subject to John B. Henneman III's continued service.
• Vested deferred stock units will settle into common stock within 45 days of the reporting person's termination of service with the issuer.

Key Dates

Keywords

Orthofix Medical Inc., OFIX, SEC Form 4, insider transaction, deferred stock units, DSU, equity award, director compensation, beneficial ownership